HC Wainwright Has Optimistic Outlook of DYN Q2 Earnings

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Stock analysts at HC Wainwright boosted their Q2 2026 EPS estimates for shares of Dyne Therapeutics in a report released on Tuesday, May 12th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings of ($0.68) per share for the quarter, up from their previous estimate of ($0.76). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($2.97) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($2.78) EPS, FY2027 earnings at ($2.27) EPS, FY2028 earnings at ($0.85) EPS, FY2029 earnings at $0.52 EPS and FY2030 earnings at $2.26 EPS.

Several other analysts have also weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Wall Street Zen lowered shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 2nd. Chardan Capital restated a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 9th. Morgan Stanley reduced their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Finally, JPMorgan Chase & Co. reduced their price target on shares of Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 20th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $35.21.

Dyne Therapeutics Price Performance

Shares of Dyne Therapeutics stock opened at $18.44 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 22.25 and a current ratio of 19.92. The firm’s 50-day simple moving average is $18.22 and its 200-day simple moving average is $18.63. Dyne Therapeutics has a twelve month low of $8.06 and a twelve month high of $25.00. The firm has a market cap of $3.05 billion, a P/E ratio of -5.73 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same quarter last year, the business earned ($1.05) EPS.

Insider Activity

In other news, Director Jason P. Rhodes sold 287,956 shares of the company’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $19.68, for a total transaction of $5,666,974.08. Following the transaction, the director directly owned 11,663 shares in the company, valued at approximately $229,527.84. This represents a 96.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,552,911 shares of company stock worth $29,694,469 in the last quarter. 14.14% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Dyne Therapeutics

A number of large investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP lifted its position in shares of Dyne Therapeutics by 870.3% during the first quarter. Dimensional Fund Advisors LP now owns 951,589 shares of the company’s stock worth $17,244,000 after purchasing an additional 853,515 shares in the last quarter. Swiss National Bank lifted its position in shares of Dyne Therapeutics by 2.5% during the first quarter. Swiss National Bank now owns 228,100 shares of the company’s stock worth $4,135,000 after purchasing an additional 5,600 shares in the last quarter. Assetmark Inc. acquired a new position in shares of Dyne Therapeutics during the first quarter worth approximately $563,000. Bank of New York Mellon Corp lifted its position in shares of Dyne Therapeutics by 13.6% during the first quarter. Bank of New York Mellon Corp now owns 401,616 shares of the company’s stock worth $7,281,000 after purchasing an additional 48,119 shares in the last quarter. Finally, Fifth Third Bancorp acquired a new position in shares of Dyne Therapeutics during the first quarter worth approximately $983,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

More Dyne Therapeutics News

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright and Lifesci Capital both raised near-term earnings estimates for Dyne Therapeutics, including Q2, Q3, and Q4 2026, suggesting analysts see a better short-term outlook for the clinical-stage biotech. Dyne Therapeutics analyst updates
• Positive Sentiment: HC Wainwright kept its Buy rating and $50 price target on DYN, reinforcing a bullish view despite the company’s ongoing losses. HC Wainwright note
• Neutral Sentiment: Dyne Therapeutics said management will participate in upcoming investor conferences, a routine investor-relations update that may help keep the stock in focus but does not by itself change fundamentals. Dyne Therapeutics investor conferences
• Negative Sentiment: Some longer-dated estimates were cut, including FY2027, FY2028, FY2029, and FY2030 EPS forecasts, which may temper enthusiasm about Dyne’s long-term earnings path. Dyne Therapeutics longer-term estimate cuts

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.